Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

1420006

USP

Levodopa Related Compound B

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

DL-3-O-Methyldopa, 3-Methoxytyrosine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
50 mg

Available to ship TODAYfromMILWAUKEE

$1,460.00

About This Item

Empirical Formula (Hill Notation):
C10H13NO4
CAS Number:
7636-26-2
Molecular Weight:
211.21
MDL number:
MFCD00063077
UNSPSC Code:
41116107
NACRES:
NA.24

$1,460.00

Available to ship TODAYDetails

​
Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(Cc1cc(c(cc1)O)OC)C(=O)O

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Levodopa
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
PHR2095PHR20961361010
USP

USP

1420006

Levodopa Related Compound B

Levodopa Related Compound A Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2095

Levodopa Related Compound A

Levodopa Related Compound B Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2096

Levodopa Related Compound B

USP

USP

1361010

Levadopa Related Compound A

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

format

neat

format

-

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical small molecule

application(s)

pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

API family

levodopa

API family

levodopa

API family

levodopa

API family

levadopa

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

Still not finding the right product?

Explore all of our products under Levodopa Related Compound B

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stephanie L Merhar et al.
Pediatrics, 116(5), 1226-1230 (2005-11-03)
Chronic bilirubin encephalopathy, characterized clinically by extrapyramidal movement abnormalities, vertical gaze abnormalities, and hearing loss, results from neuronal injury after marked hyperbilirubinemia in term and preterm infants. In premature infants, bilirubin staining of specific brain structures has been described at
Thomas Müller et al.
Naunyn-Schmiedeberg's archives of pharmacology, 383(6), 627-633 (2011-05-03)
Elevation of plasma total homocysteine concentrations were observed in levodopa/dopa decarboxylase inhibitor (DDI)-treated patients with Parkinson's disease (PD). Degradation of levodopa to 3-O-methyldopa via the enzyme catechol-O-methyltransferase (COMT) is a methyl group demanding reaction. It generates homocysteine from the methyl
T Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 114(11), 1457-1462 (2007-06-15)
The interval of line tracing performance is more associated to basal ganglia function due to the dependence on bradykinesia and rigidity. The other component of this task, the precision of execution of complex movement sequences, is more related to attention.
View All Related Papers

Global Trade Item Number

SKUGTIN
1420006-50MG04061833860533

Questions

Reviews

No rating value

Active Filters